Specialized Formulations of SN-38 for High-Security and Extreme Environments

Publication ID: 24-11857630_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Formulations of SN-38 for High-Security and Extreme Environments,” Published Technical Disclosure No. 24-11857630_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857630_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,630.

Summary of the Inventive Concept

This inventive concept adapts the original formulation of SN-38 with poly(amino acid) block polymers for specific, high-stakes applications, such as high-security medical storage, disaster relief, and extreme weather conditions.

Background and Problem Solved

The original patent disclosed formulations of SN-38 with poly(amino acid) block polymers for general chemotherapy. However, these formulations lacked the necessary adaptations for use in high-security, disaster relief, or extreme weather conditions. The new inventive concept addresses these limitations by incorporating specialized features and components to ensure the formulations remain effective and secure in these unique environments.

Detailed Description of the Inventive Concept

The new inventive concept comprises formulations of SN-38 with poly(amino acid) block polymers, tailored to meet the specific demands of high-security medical storage, disaster relief, and extreme weather conditions. For high-security medical storage, the formulation is stored in a tamper-evident container. For disaster relief, the composition is stored in a portable, waterproof container and administered to patients in need. For extreme weather conditions, the pharmaceutical kit includes a thermally-insulated container and a cryoprotectant. Additionally, the composition is adapted to withstand low atmospheric pressure for high-altitude medical treatment and compact, shock-resistant containers for emergency medical response.

Novelty and Inventive Step

The new inventive concept's novelty lies in the adaptation of the original formulation for specific, high-stakes applications, incorporating specialized features and components to ensure the formulations remain effective and secure in these unique environments. The inventive step is the recognition of the need for these adaptations and the development of tailored solutions to address these needs.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different poly(amino acid) block polymers, varying the ratio of SN-38 to polymer, or incorporating additional components to enhance stability or efficacy. Variations could also include the development of formulations for other high-stakes applications, such as space exploration or military operations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of high-security medical storage, disaster relief, and extreme weather conditions. Target industries include government agencies, humanitarian organizations, and pharmaceutical companies specializing in niche markets.

CPC Classifications

SectionClassGroup
A A61 A61K47/34
A A61 A61K9/08
A A61 A61K9/19
A A61 A61K31/4375
A A61 A61K31/513
A A61 A61K31/519
A A61 A61K45/06
A A61 A61K47/26

Field of Art

Pharmaceutical formulations, specifically chemotherapeutic drug delivery systems involving camptothecin derivatives and polymer-based drug carriers, with expertise in polymer chemistry, pharmaceutical compounding, and drug stability engineering

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or chemical engineer with advanced degree (PhD/MS) in pharmaceutical sciences, polymer chemistry, or related field, having 3-5 years experience in drug delivery system design, familiar with polymer-drug interactions and formulation techniques

Obviousness Rationale

A PHOSITA would recognize that adapting the SN-38 polymer formulation for specialized environmental conditions represents a predictable engineering solution using known techniques of pharmaceutical packaging and delivery. The core chemical composition remains substantially unchanged, with modifications focused on container design and storage parameters that are standard problem-solving approaches in pharmaceutical engineering. The variations represent routine optimization of an existing drug delivery system for specific use contexts.

Obvious Combinations & Variations

Source Patent Element
Composition comprising SN-38 and poly(amino acid) block copolymer
PTD Variation
Incorporating tamper-evident and waterproof containers for high-security and disaster relief applications
Obviousness Reasoning
Container design modifications are predictable engineering solutions for protecting pharmaceutical formulations, representing a known technique for extending drug storage capabilities
Source Patent Element
Composition with specified weight percentages of SN-38 and copolymer
PTD Variation
Adding cryoprotectant and thermal insulation for extreme weather storage
Obviousness Reasoning
Preserving drug stability through temperature management is a standard pharmaceutical engineering approach, using well-established protective strategies
Source Patent Element
Camptothecin derivative formulation with polymer carrier
PTD Variation
Adapting composition for low atmospheric pressure and high-altitude medical treatment
Obviousness Reasoning
Modifying pharmaceutical formulations for environmental stress is a routine design challenge with predictable solution strategies in drug delivery engineering
Source Patent Element
SN-38 polymer composition with flexible formulation parameters
PTD Variation
Developing shock-resistant containers for emergency medical response
Obviousness Reasoning
Protective packaging design represents an obvious extension of existing pharmaceutical storage technology, using known mechanical engineering principles
Source Patent Element
Base formulation of SN-38 with poly(amino acid) block copolymer
PTD Variation
Alternative polymer ratios and additional stabilizing components
Obviousness Reasoning
Exploring polymer composition variations is a standard approach in pharmaceutical formulation development, representing predictable scientific investigation
35 U.S.C. § 103 Summary: Based on US Patent 11857630's disclosure of SN-38 polymer formulations, the present publication demonstrates that variations in container design, environmental adaptation, and delivery context represent obvious engineering modifications that would be readily conceived by a person having ordinary skill in pharmaceutical formulation arts, thus rendering potential derivative claims obvious and anticipatable as a matter of standard pharmaceutical engineering practice.

Original Patent Information

Patent NumberUS 11,857,630
TitleFormulations of SN-38 with poly(amino acid) block polymers
Assignee(s)TYNDALL FORMULATION SERVICES, LLC